Skip to main content

Table 1 Clinical characteristics of the studied cohort (n = 66)

From: Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study

Characteristics Values (n = 66 patients)
Age at diagnosis (years)
 Median, range 51.5, 30–91
Stage
 I 13 (19.7%)
 II 39 (59.1%)
 III 12 (18.2%)
 Undetermined 2 (3.0%)
BRCA germline status (Sanger sequencing confirmed)
 BRCA1 carrier 5 (7.6%)
 BRCA2 carrier 2 (3.0%)
 BRCA-negative 59 (89.4%)
Progression status
 PFS 53 (80.3%)
 Relapse/metastasis 6 (9.1%)
 Death 1 (1.5%)
 Undetermined 6 (9.1%)
Whether (or not) treated with neoadjuvant therapy
 Yes 7 (10.6%)
 No 55 (83.3%)
 Undetermined 4 (6.1%)
Chemotherapy regimen
 TEC 16 (24.2%)
 EC-T 20 (30.3%)
 TC 3 (4.5%)
 Other 10 (15.2%)
 None 17 (25.8%)
  1. Abbreviations: PFS progression-free survival, TEC docetaxel-epirubicin-cyclophosphamide, EC-T epirubicin-cyclophosphamide followed by docetaxel, TC docetaxel-cyclophosphamide
\